Nonrigid lumbar belts for nonspecific low back pain actually work! Multicenter French trial enrolled 168 nsLBP pts - belt group had better wk 12, lower pain scores andless need for back pain medication. https://t.co/zgRclsoAR8 https://t.co/9HVwuE1YLz

Tune in for an expert conversation on the latest data from SELECT-SWITCH, including discussion about the EULAR 2026 post hoc analysis of primary and secondary TNFi nonresponders. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/Fkdgk1T7qm https://t.co/quqgOLDMjL

Italian SPRING cohort of #SSc pts found only 5.3% (of 1689 pts) without the typical scleroderma pattern on nailfold change by NVC. They had milder dz, with less vascular dz (pitting scars 33 vs 48%), telangiectasias (52 vs 74%), calcinosis 3.4 vs 12%) & higher DLCOs at 12, 24, https://t.co/AoNAhVYfII

Retrospective Medicare comparison 450 paired #PMR cohorts Rx w/ IL-6 inhib or csDMARDs. At 1 yr, IL-6i pts (vs csDMARD) had signif more GC D/C (adj HR 1.28) or minimal GC use (<3mg/d) (aHR 1.28). Hosp. infxn 2X higher in IL-6i (12.2 vs 5.7 per 100 PY) in year 1, but not year 2 https://t.co/YgqLjD9nvM

Prolonged exposure to targeted Rx in #SpA not assoc w/ increased cancer risk. French claims study 56,591 SpA pts- 1,224 CA (1,029 solid, 116 Heme). TNFi, IL17i, IL12/23i, IL23i, JAKi Exposure >6 vs ≤6 mos assoc w/ lower CA (HR 0.86; 0.75-0.99); signif for Heme (HR 0.65), not https://t.co/rHAa0CkAjT

How do rheumatologists & radiologists team up to tackle autoimmune ILD? Hear from Drs. Elizabeth Volkmann & Robert Suh, and patient mentor Carolyn, on the diagnosis, monitoring & patient journey. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. https://t.co/zrpMBDqWdg https://t.co/sc8OfpPoR6

EU Finalizes Tavneos Withdrawal - The European Commission has officially revoked the marketing authorization for Tavneos (avacopan), finalizing a process that began with regulators flagging the drug's pivotal trial data as "incorrect and misleading." The EC issued its legally https://t.co/jgysiV1hyX

QD Clinic: A Watched Tophus Never Resolves Dr. Jack Cush discusses his plan to medically manage multiple large volume tophi and a patient who has recently started urate lowering therapy with febuxostat. https://t.co/swfyYEeW0s https://t.co/wyLlcHR4Td

Efgartigimod Efficacy in Idiopathic Inflammatory Myopathy Today Argenx announced the results of their Phase 3 "ALKIVIA" study; demonstrating efficacy and safety of subcutaneous efgartigimod for Idiopathic Inflammatory Myopathy (IIM, AKA inflammatory myositis). https://t.co/TYP4KcdLoa

Can Effective Psoriasis Therapy Prevent Psoriatic Arthritis? A review article assesses and integrates mechanistic, imaging, and clinical evidence to examine whether effective treatment of psoriasis may modify the future risk of psoriatic arthritis (PsA). https://t.co/3gnV3eaKiu

In 2026 Abbvie granted 34 scholarships to students With Inflammatory Diseases. In the last 10 yrs, theyve granted $6 million to >350 students in the US for higher education. These awards up to $20,000 per student renewable up to 4 yrs. https://t.co/DFy5SukB6G https://t.co/9mVkrhL2lo

Doubting RS3PE (8.14.2026) Dr. Jack Cush reviews the news and journal articles this week where RheumNow featured info on cancer, deadly viruses, AI rules, poetry and good moons rising. https://t.co/gmcrjb5bDu https://t.co/LiLl7XcZQS

Multiple chronic conditions (MCCs; AKA multimorbidity) is highly prevalent in AIRDs; complicates Rx & increases adverse outcomes & all-cause mortality. MMCs 86% in RA, 81.5% in SLE, w/ a notable patterns of cardiopulmonary and mental health disorders https://t.co/AOWCsEodXR https://t.co/NyAR0TUQkE